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Introduction
The treatment of multiple myeloma (MM)
has changed dramatically in the past twenty
years with the introduction of high-dose thera-
py  plus  autologous  stem-cell  transplantation
(ASCT) in younger patients and, more recent-
ly, of three novel agents (thalidomide, borte-
zomib, and lenalidomide). 
When conventional chemotherapy was the
only available possibility, complete responses
(CR) were very rare and the objective of main-
tenance was to prolong remission duration by
continuing  the  same  type  of  treatment  that
induced the initial response. With recent ther-
apeutic  improvements,  CR  achievement
becomes a realistic goal that, in most cases, is
significantly  correlated  with  the  outcome.
1
Therefore, both the nature and the impact of
maintenance  therapy  have  changed.
Maintenance  therapy  is  based  currently  on
novel agents, and its objective is not only to
control the clone but also to further decrease
the tumor burden and improve the quality of
response.
A  number  of  randomized  studies  show  a
benefit from maintenance therapy with novel
agents  (until  now,  mostly  thalidomide),  at
least in terms of response rate and progres-
sion-free survival (PFS). However, there is still
a debate as concerns the impact on overall sur-
vival (OS) and the optimal administration of
maintenance therapy.
Maintenance therapy in the
pre-thalidomide era
In patients initially treated with convention-
al chemotherapy, maintenance chemotherapy
has failed to demonstrate any significant ben-
efit.
2,3 Therefore, the recommendation was to
stop chemotherapy once stable response had
been achieved (the so-called plateau phase). 
One study showed a survival advantage for
patients  receiving  alternate-day  prednisone
maintenance therapy at a dose of 50 mg when
compared with 10 mg after standard induction
chemotherapy.
4
In the nineteen-eighties α-interferon main-
tenance  therapy  represented  a  great  hope.
Following the initial randomized study show-
ing  prolonged  remissions  with  α-interferon
maintenance  in  patients  responding  to  con-
ventional induction therapy,
5 a number of ran-
domized  trials  were  performed  but  their
results were controversial.
6 Two meta-analyses
of randomized trials showed that with interfer-
on  maintenance,  time  to  PFS  and  OS  was
increased by four to seven months.
7,8 However,
most investigators considered that the benefit
was small and needed balancing against cost
and potential toxicity of prolonged treatment
with α-interferon.
In  addition,  α-interferon  has  been  used
after ASCT, with the hypothesis that it might
be  more  effective  in  patients  with  minimal
residual disease. In a retrospective analysis of
the  European  Bone  Marrow  and  Blood
Transplant  Registry,  interferon  maintenance
was associated with improved PFS and OS in
patients  responding  to  high-dose  therapy.
9
However, two randomized trials failed to con-
firm this result.
10,11
Thalidomide as maintenance
therapy after autologous 
stem-cell transplantation
When  thalidomide  maintenance  therapy
was first introduced in the field of ASCT for
MM, the median duration of response did not
exceed three years and almost all patients did
relapse ultimately.
12 Six randomized trials have
evaluated the impact of thalidomide mainte-
nance after ASCT in MM.
12-17 However, these
trials differed in their design and in the dose
and  duration  of  thalidomide  maintenance
(Table 1).
In two of these studies, patients were ran-
domized  initially  to  receive  thalidomide
throughout their treatment (both before and
after ASCT).
13,17 Therefore, the putative impact
of thalidomide was not expected to be a result
of the maintenance effect only.
In the other four studies, patients were ran-
domized after ASCT to receive either thalido-
mide or not. While in two of these trials the
control group was to receive no further treat-
ment,
12,16 in the Tunisian study by Abdelkefi et
al. (2008), thalidomide maintenance was com-
pared to a second ASCT,
14 and in the Australian
study by Spencer et al. (2009) the combination
of thalidomide plus alternate-day prednisone
was compared to the administration of pred-
nisone alone.
15
In two of these trials, patients were random-
ized  only  if  they  were  not  progressing  after
induction treatment plus ASCT,
12,15 while in the
other two studies, all patients were random-
ized,  whatever  the  degree  of  post-ASCT
response.
14,16 Finally,  in  the  French  and
Australian studies by Attal et al. (2006) and
Spencer et al. (2009), respectively,
12,15 thalido-
mide was not used during induction treatment.
In the British study by Morgan et al. (2008),
there was an initial randomization at diagno-
sis (thalidomide versus no thalidomide),
16 and
in  the  Tunisian  study  by  Abdelkefi  et  al.
(2008), all patients received thalidomide plus
dexamethasone as induction treatment prior
to ASCT.
14
In four of these six trials, thalidomide was
prescribed until relapse or until severe adverse
event, while in the studies by Abdelkefi et al.
(2008) and Spencer et al. (2009), the duration
of thalidomide was fixed (six months in the
Tunisian  study  and  12  months  in  the
Australian study).
14,15 The daily dose of thalido-
mide  varied  from  100  mg/day
14 to  an  initial
dose of 400 mg/day in the first two of the six
studies.
12,13 Despite  these  disparities,  all  six
studies showed a benefit in favor of thalido-
mide in terms of response rate (CR, or greater
than or equal to very good partial remission
and PFS) (Table 2).
Results are not that clear-cut as regards OS.
While in the initial publication of the French
and Tunisian studies
12,14 OS was significantly
longer in the thalidomide trials, with longer
follow-up this survival advantage disappeared,
and Aldelkefi et al. (2009) did publish a retrac-
tion recently.
18
On the contrary, the first publication from
the Arkansas group showed no significant dif-
ference  in  OS  between  the  two  groups,
because  of  a  shorter  OS  after  relapse  in
patients  initially  treated  with  thalidomide.
11
However,  with  a  longer  follow-up,  the  OS
curves  diverge  after  five  years.
19 A  second
report  of  the  same  trial,  showed  a  trend  in
favor of thalidomide and a significant benefit
in  the  subgroup  of  patients  with  karyotypic
abnormalities.
13 In the Dutch (Lokhorst et al.,
2008) and British ) and British (Morgan et al.,
2008) studies, the PFS benefit did not translate
into a significant OS benefit, again because of
a shorter OS after relapse in the thalidomide
group.
16,17
Hematology Reviews 2009; volume 1:e12
Correspondence:  Jean-Luc  Harousseau,  Rene
Gauducheau Cancer Center, Bd Jacques Monod
44805, Nantes/St Herblain Cedex, France
E-mail: jl-harousseau@nantes.fnclcc.fr
Received for publication: 23 July 2009.
Accepted for publication: 1 August 2009.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0)
©Copyright J.-L. Harousseau 2009
Licensee PAGEPress, Italy
Hematology Reviews 2009; 1:e12
doi:10.4081/hr.2009.e12How can we analyze these differ-
ences?
The first message is that OS data should not
be analyzed and published too early. In the past
the only possibility at relapse was convention-
al chemotherapy. Currently we have more pos-
sibilities (e.g., ASCT, thalidomide and lenalido-
mide, bortezomib), and survival after relapse
may be longer than duration of first response.
Since it is possible to achieve median OS of
more  than  or  equal  to  five  years  now,  OS
should not be analyzed before at least five-year
median follow-up time.
Secondly, OS obviously depends on salvage
treatments. If thalidomide is prescribed until
relapse or severe toxicity, one can imagine that
thalidomide  should  not  be  used  at  relapse.
Therefore, more patients receive thalidomide
at relapse in the no-thalidomide trials, and the
design  of  these  studies  is  rather  early  (up
front)  thalidomide  versus  late  (at  relapse)
thalidomide. This was actually the case with
ASCT:  in  randomized  trials  comparing  ASCT
and  conventional  chemotherapy,  ASCT  was
superior  in  terms  of  PFS  but  not  always  in
terms  of  OS,  partly  because  patients  in  the
conventional  chemotherapy  group  could
receive ASCT at relapse.
20 A randomized study
comparing early versus late ASCT showed no
significant difference in terms of OS.
21
Moreover,  the  risk  of  thalidomide-induced
peripheral neuropathy is clearly related to the
cumulative dose, and prolonged exposure car-
ries the risk of severe neuropathy, precluding
or limiting the use of bortezomib. Prolonged
exposure to thalidomide might select clones
resistant not only to thalidomide but also to
other agents. We already know that lenalido-
mide is less effective in patients resistant to
thalidomide  than  in  thalidomide-naïve
patients.
22
Finally,  salvage  treatment  depends  on  the
availability of novel agents. When the British
trial by Morgan et al. (2008) was performed,
there was a limited access to bortezomib, and
lenalidomide was not available except for clin-
ical trials. Therefore there were more thera-
peutic possibilities (including thalidomide) at
relapse in the no-thalidomide group.
These considerations clearly raise the issue
of the optimal duration of maintenance thera-
py. Should it be fixed as in the Tunisian or
Australian studies,
14,15 or unlimited as in the
other four studies?
12,13,16,17 The theoretical inter-
est  of  prolonged  maintenance  is  to  further
improve the level of tumor burden reduction,
hence prolonging PFS but, on the other hand,
this benefit might be hampered by reduced sal-
vage  possibilities,  hence  a  shorter  OS  after
relapse. A randomized study addressing this
question might be extremely useful.
Additional questions
What is the optimal schedule of adminis-
tration?
In the first two studies by Attal et al. (2006)
and  Barlogie  et  al.  (2006),  the  initial  daily
dosage was high (400 mg) and the duration of
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Table 1. Post-ASCT maintenance with thalidomide: randomized studies.
Author Induction ASCT Thalidomide administration Design
Attal et al.
12 No Thal Double Starting dose 400 mg/d until relapse After ASCT (if no progression)
No treatment vs. Thal + Pamidronate
Barlogie et al.
13 50% Thal Double Starting dose 400 mg/d until relapse Initial randomization Thal vs. no Thal
Abdelkefi et al.
14 Thal Single + Thal vs. double 100 mg/d for 6 months After ASCT
Spencer et al.
15 No Thal Single 20 mg/d for 1 year After ASCT (if no progression)
Morgan et al.
16 50% Thal Single 100 mg/d until relapse After ASCT
Lokhorst et al.
17 50% Thal Double 200 mg/d until relapse Initial randomization
TAD ₒThal
VAD ₒIFN
ASCT, autologous stem cell transplantation; Thal, thalidomide; d, day; TAD, thalidomide adriamycin dexametasone; VAD, vincristine adriamycin dexamethasone; IFN, interferon.
Table 2. Results of randomized studies on post-ASCT maintenance with thalidomide. 
Author N. of  Median  Response  PFS or EFS OS initial  OS updated
patients follow-up rate publications results
Barlogie et al.
13 668 42 m 62% vs. 43% 5-year EFS 5-year OS p=0.09
p<0.001 56% vs. 44% 65% vs. 65%
p=0.01
Attal et al
12 597 40 m *67% vs. 55% or 57% 3-year EFS 4-year NS
p=0.03 52% vs. 37% 87% vs. 75% p=0.04
p=0.002
Abdelkefi et al.
14 195 33 m *68% vs. 54% 3-year PFS 3-year NS
p=0.04 85% vs. 57% 85% vs. 65% p=0.04
p=0.02
Spencer et al.
15 269 3 y 65% vs. 44%* 3-year PFS 3-year ND
p<0.001 42% vs. 23% 86% vs. 75%
p<0.001 p<0.004
Morgan et al.
16 820** 32 m NA Better in patients  NS ND
with < VGPR Median OS
p<0.007
Lokhorst et al.
17 556 52 m *66% vs. 54% Median EFS 73 m vs. 60 m ND
p=0.005 34 m vs. 22 m p=0.77
p<0.001
*, complete response; +, very good partial response (VGPR); **, including patients receiving non-intensive induction; ASCT, autologous stem cell transplantation; PFS, progression-free survival; EFS, event-free sur-
vival; OS, overall survival; NS, not significant; m, months; y, years; ND, not done; NA, not available.
Articletreatment was unlimited, which explains the
high incidence of severe neuropathy (Grade
≥3), as well as the percentage of patients who
discontinued treatment because of toxicity.
12,13
Although no randomized study has compared
different schedules of administration, doses of
100  mg  or  200  mg/day  during  6-12  months
appear to be effective and better tolerated.
13,14
Is thalidomide maintenance useful for all
patients, and are we able to predict
patients who will benefit from maintenance
therapy?
Unfortunately there is no clear response to
this question. In the French study by Barlogie
et al. (2006), patients with del
13 apparently did
not benefit from thalidomide maintenance, but
at the time of this trial other abnormalities
that  are  frequently  associated  with  del(13),
such as t(4;14) or 17p del, were not routinely
studied.
12 We know now that the negative prog-
nostic impact of del(13) is mostly a result of
these two additional abnormalities.
23 We have
no published data on the impact of thalidomide
in this subgroup of patients with these poor-
risk abnormalities, although in a preliminary
report  (Lokhorst  et  al.,  2008),  thalidomide
appeared  to  perform  poorly  in  patients  with
del(17p).
17
In  the  updated  analysis  of  the  Arkansas
study by Adelkefi et al.(2009), thalidomide sig-
nificantly improved OS of patients with cytoge-
netic abnormalities as defined by conventional
karyotyping.
18 This heterogeneous subgroup of
patients generally is considered as poor-risk,
since  the  possibility  of  studying  mitoses  is
associated with a more proliferative disease.
Finally, in the studies by Attal et al. (2006)
and Morgan et al.(2008), only patients who did
not  achieve  at  least  a  very  good  partial
response  (VGPR)  after  transplant  benefitted
from thalidomide maintenance,
12,16but this was
not confirmed by Spencer et al. (2009).
15
Does thalidomide act as a maintenance or
consolidation therapy?
In all the studies reviewed, the PFS prolon-
gation was associated with a CR or CR/VGPR
increase. Moreover, the fact that patients who
showed CR after ASCT did not benefit from
thalidomide  in  at  least  two  of  the  studies
could mean that thalidomide might act more
by increasing the post-ASCT CR rate than by
controlling the residual clone. In other words,
post-ASCT  thalidomide  might  be  considered
as  a  consolidation  therapy,  and  might  be
administered  with  the  objective  of  further
decreasing the tumor burden. If this is true,
we still have to determine the optimal level of
response.  Is  CR  with  negative  immunofixa-
tion the requested level or should we try to
obtain  higher  levels  of  response  (stringent
response,  immunophenotypic  response,  or
even molecular response)? 
This  important  question  should  be
addressed in future trials. To date, Paiva et al.
(2008)  have  shown  that  immunophenotypic
CR,  as  assessed  by  multi-parameter  flow
cytometry, is associated with a better outcome
than CR as defined only by immunofixation.
24
Other novel agents as mainte-
nance therapy after autologous
stem-cell transplantation
Lenalidomide, which is better tolerated than
thalidomide and can be prescribed safely for
long periods of time, appears to be an ideal
candidate for maintenance therapy. However,
this  agent  is  more  myelotoxic  than  thalido-
mide  and  the  optimal  dose  of  lenalidomide
after  high-dose  therapy  is  not  known.  Two
large randomized trials from the Intergroupe
Francophone  du  Myelome  (IFM  )  and  the
Cancer and Acute Leukemia Group B (CALGB)
groups  have  tested  lenalidomide  as  mainte-
nance after ASCT, but results of these studies
are not available.
In addition, bortezomib has been evaluated
in  this  setting  by  Morgan  et  al. (2008)  and
Paiva  et  al. (2008).
16,24 Since  bortezomib  is
associated with a high incidence of peripheral
neuropathy when used on a bi-weekly schedule
at a dose of 1.3 mg/m
2, the issue of the toxici-
ty/efficacy ratio is crucial. 
If the objective of post-ASCT therapy is to
increase the level of response with a consolida-
tion effect further, short-term treatment with
combinations of novel agents might be attrac-
tive  as  well.  Ladetto  et  al. (2008)  recently
showed encouraging results with four courses
of  consolidation  treatment  with  bortezomib-
thalidomide-dexamethasone.
25 In  this  study,
six out of 24 patients, who were at least in
VGPR after ASCT, achieved molecular remis-
sions and none of them had a relapse with a
median follow-up of 26 months.
Novel agents as maintenance
therapy after allogeneic 
stem-cell transplantation
Currently, allogeneic stem-cell transplanta-
tion (allo-SCT) following a myeloablative con-
ditioning regimen has almost been abandoned
in  MM  because  of  excessive  toxicity.
26
Reduced-intensity  conditioning  is  associated
with reduced transplant-related mortality but
with increased relapse rate compared to stan-
dard allo-SCT.
27In order to decrease the relapse
rate,  a  strategy  with  tandem  ASCT-reduced
intensity  conditioning  allo-SCT  is  currently
proposed. However, relapses remain frequent,
especially in the absence of chronic-graft ver-
sus host disease.
26 Therefore, post-transplant
immunotherapy  with  donor-lymphocyte  infu-
sions and/or novel agents has been tested with
the  objective  of  upgrading  the  level  of
response. In a preliminary experience, Kroger
et  al. (2009)  have  proposed  novel  agents
(thalidomide, bortezomib, or lenalidomide) to
patients who were not in CR after allo-SCT and
donor lymphocyte infusions.
28 They could con-
vert partial remission to CR in 59% of patients
and  to  molecular  remissions  in  50%  of
patients.
Thalidomide maintenance 
therapy after non-intensive
induction treatment
In a recent trial Ludwig et al. (2009) evalu-
ated  thalidomide  plus  interferon  compared
with interferon alone in 135 elderly patients
with  at  least  stable  disease  after  induction
treatment with either thalidomide dexametha-
sone or melphalan-prednisone (MP). Athough
PFS  was  significantly  longer  in  the  thalido-
mide  group  (24  months  versus  13  months,
p>0.024), OS was similar in both groups.
29
Five  randomized  trials  have  compared  MP
and MP plus thalidomide (MPT) as the primary
treatment in elderly patients.
30-35 Although the
design of these studies and the inclusion crite-
ria were slightly different, all five studies have
shown a benefit of MPT in terms of response
rate, and PFS was significantly longer in the
MPT groups of four out of five studies (Table 3). 
However,  in  only  two  studies  this  benefit
translated  into  a  significantly  longer  sur-
vival,
32,33 and in these two studies there was no
maintenance  while  in  the  other  three  trials
there  was  a  maintenance  with  thalidomide
alone in the MPT groups. In the Italian study by
Palumbo  et  al. (2008),  the  shorter  survival
after  relapse  in  the  MPT  group  might  have
been  explained  by  a  lower  percentage  of
patients  receiving  thalidomide  as  salvage
treatment at relapse.
31 Since the three studies
were not designed to address the question of
maintenance, it is not possible to consider that
the lack of survival benefit in the MPT group is
related to maintenance thalidomide. However,
one can conclude from these studies that there
is no evidence that maintenance thalidomide
is  useful  in  elderly  patients  initially  treated
with MPT. Until now, in elderly patients, avail-
able data do not show a benefit from mainte-
nance treatment with thalidomide, at least in
terms of OS. At least two randomized studies
addressing the question of maintenance treat-
ment with lenalidomide in elderly patients are
ongoing.
Type of paper
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ArticleConclusions
In  younger  patients,  post-ASCT  mainte-
nance  therapy  with  thalidomide  appears  to
increase  tumor  burden  reduction  further,
which translates in prolonged PFS. However,
the benefit in terms of OS is not clear and
many questions remain regarding the respec-
tive role of consolidation versus maintenance,
the optimal drug and the optimal schedule of
administration and duration of treatment, as
well as the characteristics of patients who may
benefit from this approach. In elderly patients
there  is  currently  no  evidence  that  mainte-
nance treatment improves OS.
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